| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3286297 | Clinics and Research in Hepatology and Gastroenterology | 2011 | 7 Pages |
Abstract
The toxicity of high-dose CPT11Â +Â LV5FU2 chemotherapy was well tolerated when the dose was progressively increased according to individual tolerability, with 37% of patients receiving CPT11 at 260Â mg/m2. Progression-free survival (PFS) increased with higher doses of CPT11. In the chemo-naive and pretreated subgroups, the median PFS was 10.9 and 8.8Â months, respectively (PÂ =Â 0.698, NS). Optimization of CPT11 doses in pretreated patients appears to pave the way for new treatment options.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
L. Mineur, R. Sabatier, S. Kirscher, F. Plat, Y. Goubely, N. Molinari,